Business Wire

AMCS unveils the AMCS Platform Summer ‘23 edition, the second release this year, delivering exciting new productivity features and a dynamic customer experience for environmental, transportation, waste, recycling and resource operators

10.7.2023 18:15:00 EEST | Business Wire | Press release

Share

AMCS, the world leading technology provider for the environmental, waste, recycling and environmental health and safety industries, today announced the global launch of the AMCS Platform 2023 Summer release. The release offers important new benefits and features, including:

  • Order-to-Cash Automation to simplify and accelerate cashflow – Newly streamlined and optimised processes enable operators to invoice faster and more easily, so they can get paid sooner, creating a better experience for both users and customers. A new cash collection management module provides automated credit control to collect all receivables.
  • Maximised Asset Utilisation – The new Equipment Inventory module optimises visibility and control over container assets by quickly identifying slow-moving containers, ensuring they’re available to meet market demand, and allowing operators to optimise sales and minimise the costs associated with the physical loss of containers.

    Significant enhancements to the Transport Solutions platform user experience will boost scheduling and maintenance productivity of both fleet owners and planners, empowering them to optimise utilisation of company fleet assets.
  • Digitalisation of Purchase to Pay – A streamlined process will allow recyclers to seamlessly manage tickets for the purchase of feedstock. Scrap recyclers can capture supplier data quickly and easily to ensure regulatory compliance. Integrated, flexible supplier payments allow cash (including ATM), check, and ACH, as well as exciting emerging digital instant payment types (using AMCS Pay) including push-to-debit and pre-paid cards. These connected, digitalised processes will automate, connect, and accelerate purchasing, compliance, scale, supplier payment, and financial tasks, boosting both efficiency and competitiveness.

“Our continued investment in automation processes is the major theme of the AMCS Platform. The Summer ’23 release delivers real business value,” says Elaine Treacy, Global Product Director at AMCS. Treacy continues, “Newly optimised ‘order to cash’ processes will drive faster payments with less effort, reducing the risk of overdue payments and bad debt. Our new streamlined ‘purchase to pay‘enables recyclers to purchase feedstock in an efficient and regulatory compliant manner. In addition to supplier settlements using cash and checks, we are introducing exciting digital payment options.”

The investment in enhanced user experiences and a new equipment inventory feature will allow AMCS customers to drive greater utilisation and financial return from their container and truck assets, and thus improve their sales. Other highlights of the summer release include:

  • Full integration of AMCS Vision AI into the AMCS Platform, providing new dashboards for insight as well as options to automatically charge for exceptions such as overfills and contamination.
  • A new Sustainability Dashboard on the AMCS Customer Portal, allowing customers to share key sustainability performance metrics with their end users.
  • New Customer Self-Serve features, including support for Interactive Voice Response (IVR) for PCI compliant payments and the digital exchange of Duty of Care (UK) compliance documentation.
  • For municipal operators, more streamlined invoice processing of direct residential subscribers and enhanced controls on the service status of customers, depending on their payment standing.
  • A new and improved AMCS Academy online customer training platform, with more compelling and engaging training experiences.

To learn more about AMCS Platform Summer ‘23 Release, visit www.amcsgroup.com

About AMCS Group

AMCS, with offices in Europe, North America and Australia is a global technology leader for the environmental, waste, recycling, and resource industries. We help over 4,000 customers reduce their operating costs, increase asset utilisation, optimise margins, drive sustainability, and improve customer service. Our enterprise software and SaaS solutions deliver digital innovation to the emerging circular economy around the world. Read more about AMCS at www.amcsgroup.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Austen Lees
Sirius Communications
austen@siriuscomms.co.uk
Tel.: 00447773813210

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye